GSK begins Phase III diabetes trial of GLP-1 agonist Syncria
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has begun Phase III trials of its long-acting GLP-1receptor agonist Syncria (albiglutide) for the treatment of type2 diabetes.